The recombinant human endostatin improves the blood perfusion and hypoxia in non-small cell lung cancer
10.3760/cma.j.issn.0254-9026.2011.09.009
- VernacularTitle:重组人血管内皮抑素对非小细胞肺癌患者血流灌注和乏氧改善作用的观察
- Author:
Xiaodong JIANG
;
Peng DAI
;
Jin WU
;
Daan SONG
;
Jinming YU
- Publication Type:Journal Article
- Keywords:
Endostatins;
Carcinoma,non-small-cell lung;
Diagnostic imaging
- From:
Chinese Journal of Geriatrics
2011;30(9):737-741
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the dynamic changes of blood perfusion and hypoxic status by CT perfusion imaging and hypoxia imaging in patients with non-small cell lung cancer (NSCLC) after treatment with recombinant human endostatin (RHES). MethodsA total 15 patients with NSCLC were randomly divided into treatment group (n = 10) and control group (n = 5). The patients in treatment group continuouly received the treatment with RHES (7.5 mg/m2) by intravenous infusion for ten days, and CT perfusion imaging and hypoxia imaging were performed at day 1, 5 and 10,respectively. The time window' was observed with the blood perfusion status and hypoxic changes.ResultsIn the treatment group, capillary permeability surface (PS) and tumor to normal tissue (T/N) were firstly decreased, and then increased. Their lowest points occurred at about the fifth day. PS showed statistical significance compared with the first day (q1.5 = 12.05, P＜0.01 ) and no significance compared with the tenth day(q10.5 = 2.79, P=0.69), while T/N showed a significant difference between above time points (q1.5 = 73.81, q10.5 = 20.6, P = 0.00).Blood flow (BF) was firstly increased, and then decreased.Its highest point appeared at about the fifth day with statistical significance compared with the first and tenth day (q1.5 = 12.29, q10.5 = 10.48, P＜0.01 ). All the PS,BF and T/N between the fifth day in treatment group and the control group showed statistically significance (all P ＜ 0.01 ).Conclusions The time window of recombinant human endostatin improving blood perfusion and hypoxic status in non-small cell lung cancer is within about one week after administration.
